What is Caribou Biosciences, Inc. (CRBU)?

Caribou Biosciences, Inc. (CRBU) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of CRBU?

The current price of CRBU is $0.49. Prices are updated in real time on Stocks360.

What is CRBU's price-to-earnings (PE) ratio?

CRBU's trailing twelve-month PE ratio is -0.45, based on current price and earnings per share data available on Stocks360.

What is CRBU's market capitalization?

CRBU's market capitalization is $52,467,357.00, placing it in the small-cap tier.

Caribou Biosciences, Inc. (CRBU)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$0.49

Market Cap

$52.47M

PE (TTM)

-0.45

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

2.31

Day Range

$0.46 – $0.49

52-wk Range

$0.44 – $3.54

Avg Volume

N/A

Volume

1.01M

Caribou Biosciences, Inc. (CRBU) is a publicly traded company in the Healthcare sector. Latest price: $0.49. Market cap $52.47M. Trailing PE -0.45. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $2.37 2026-10-28 · $0.49 (-79.35%)

Earnings

Most Recent

Aug 13, 2026

EPS $-0.24 vs est. $-0.32

Beat by $0.08

Next Earnings

Nov 11, 2026

EPS estimate $-0.27

Proprietary Signals

Signal snapshot temporarily unavailable.

About Caribou Biosciences, Inc.

Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.45×
P/S (TTM)	5.23×
P/B	0.50×
P/FCF (TTM)	-0.55×
EV / EBITDA	-0.51×
EV / Sales	5.27×
Earnings Yield	-209.22%
Free Cash Flow Yield	-182.50%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$52.93M
Revenue (TTM)	$10.04M
Net Income (TTM)	-$109.77M
Free Cash Flow (TTM)	-$95.75M
Net Debt	$461.00K
Working Capital	$98.62M
Gross Margin	-129.70%
Operating Margin	-1090.90%
Net Margin	-1030.42%
Return on Equity	-89.11%
Return on Invested Capital	-86.30%